594839-88-0

594839-88-0 structure

Name: Tafamidis
Chemical Name: tafamidis
CAS Number: 594839-88-0
Molecular Formula: C₁₄H₇Cl₂NO₃
Molecular Weight: 308.116
Catalog: Research Areas Neurological Disease
Create Date: 2019-02-15 19:23:56
Modify Date: 2026-07-09 22:48:55
Tafamidis(Fx1006A) is a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.Target: OthersTafamidis is a drug for the amelioration of transthyretin-related hereditary amyloidosis.Tafamidis functions by kinetic stabilization of the correctly folded tetrameric form of the transthyretin (TTR) protein. Tafamidis binds selectively and with negative cooperativity (K(d)s ~2 nM and ~200 nM) to the two normally unoccupied thyroxine-binding sites of the tetramer, and kinetically stabilizes TTR. Patient-derived amyloidogenic variants of TTR, including kinetically and thermodynamically less stable mutants, are also stabilized by tafamidis binding. The crystal structure of tafamidis-bound TTR suggests that binding stabilizes the weaker dimer-dimer interface against dissociation, the rate-limiting step of amyloidogenesis [1].

Name	tafamidis
Synonyms	FX-1006A;FX1006A;FX 1006A Fx1006A UNII-8FG9H9D31J 3MI Tafamidis (Fx1006A) Chlorfenazolac Tafamidis, 10 mM in DMSO Tafamidis free acid 2-(3,5-Dichlorophenyl)-6-benzoxazole cboxylic acid Tafamidis free acid, 2-(3,5-dichlorophenyl)-6-benzoxazole cboxylic acid 8FG9H9D31J 2-(3,5-Dichlorophenyl)benzoxazole-6-cboxylic Acid afamidis (Fx1006A) 2-(3,5-Dichlorophenyl)-1,3-Benzoxazole-6-cboxylic acid 2-(3,5-Dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid PF-06291826(Tafamidis) Fx 1006A D3-Tafamidis FX-1006 Fx-1006A 2-(3,5-Dichlorophenyl)benzo[d]oxazole-6-cboxylic acid 6-Benzoxazolecboxylic acid, 2-(3,5-dichlorophenyl) Tafamidis API TafaMidis

Description	Tafamidis(Fx1006A) is a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.Target: OthersTafamidis is a drug for the amelioration of transthyretin-related hereditary amyloidosis.Tafamidis functions by kinetic stabilization of the correctly folded tetrameric form of the transthyretin (TTR) protein. Tafamidis binds selectively and with negative cooperativity (K(d)s ~2 nM and ~200 nM) to the two normally unoccupied thyroxine-binding sites of the tetramer, and kinetically stabilizes TTR. Patient-derived amyloidogenic variants of TTR, including kinetically and thermodynamically less stable mutants, are also stabilized by tafamidis binding. The crystal structure of tafamidis-bound TTR suggests that binding stabilizes the weaker dimer-dimer interface against dissociation, the rate-limiting step of amyloidogenesis [1].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Neurological Disease
References	[1]. Bulawa, C.E., et al., Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A, 2012. 109(24): p. 9629-34.